Get access to our best features

U.S. FDA approves Amylyx ALS drug

Summary by Ground News
The FDA has approved an Amylyx Pharmaceuticals drug for amyotrophic lateral sclerosis (ALS) Relyvrio is a combination of two compounds, tauroursodeoxycholic acid and sodium phenylbutyrate, which together are intended to lead to longer survival of neurons. No serious adverse events were reported from the study.
2 months ago·Washington, United States

News Articles

More Filters
All
Left
Center
Right

U.S. FDA approves Amylyx ALS drug

The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc's (AMLX.O) drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.

2 months ago·United Kingdom
Read Full Article

ALS drug wins U.S. FDA approval despite questionable data

A much-debated drug for Lou Gehrig's disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.

2 months ago·Toronto, Canada
Read Full Article

ALS drug wins FDA approval despite questionable data

U.S. health officials have approved a much-debated drug to treat the deadly illness known as Lou Gehrig's disease. The approval Thursday follows an intense lobbying campaign by patients and advocates,

2 months ago·United States
Read Full Article

ALS drug wins FDA approval despite questionable data

U.S. health officials have approved a much-debated drug to treat the deadly illness known as Lou Gehrig's disease

2 months ago·United States
Read Full Article

ALS drug gets FDA approval despite uncertainty about effectiveness

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration.

2 months ago·Atlanta, United States
Read Full Article

F.D.A. Approves A.L.S. Treatment Despite Questions About Effectiveness

The drug is safe, and one trial found it may extend survival and slow paralysis in functions like muscle control and speaking. A larger trial will be completed in 2024.

2 months ago·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

75% of the sources are Center
CNN
Associated Press News
abc News
New York Times
The Washington Post
abc 6 Philadelphia
NBC News
+13
Reuters
CTV News
KVIA
KIFI
KCRA 3
abc 7 NY
+66
Financial Post
Boston Herald
Wall Street Journal
UnionLeader.com
The National Herald
L 20%
C 75%
 
See less detail